麦克森公司和私募股权公司 Clayton Dubilier & Rice 将以约 58 亿美元的企业价值收购 Option Care Health Inc.，进军医疗输液领域。
McKesson Corp. and the private equity firm Clayton Dubilier & Rice will buy Option Care Health Inc. for an enterprise value of about $5.8 billion, expanding into the medical infusion space.
两家公司在声明中表示，CD&R 将持有 Option Care 的多数股权，后者将继续由其自身管理团队领导。麦克森将投资约 14 亿美元，获得约 49% 的股权。周二纽约常规交易开始前，Option Care 股票停牌。在《金融时报》报道收购谈判后，其股价隔夜飙升逾 20%。收购价较 Option 周一收盘价溢价 37%。交易预计将于 2027 年上半年完成。
CD&R will hold a majority ownership interest in Option Care, which will continue to be led by its own management team, the companies said in a statement. McKesson will invest roughly $1.4 billion for about 49% interest in the company. Option Care shares were halted before the start of regular trading in New York on Tuesday. They surged more than 20% overnight after the Financial Times reported the deal talks. The acquisition price marks a 37% premium from Option’s closing share price on Monday. The deal is expected to close in the first half of 2027.